Results 41 to 50 of about 687 (166)

Is Intralesional Methotrexate an Effective Alternative to Intralesional Triamcinolone in Alopecia Areata? Findings From a Randomized Controlled Trial

Journal of Cosmetic Dermatology, Volume 24, Issue 8, August 2025.
ABSTRACT Background Alopecia areata (AA) is an autoimmune condition resulting in hair loss, sometimes just in small patches but occasionally across larger areas like the entire scalp. For localized AA, treatments often involve injecting corticosteroids, such as triamcinolone acetonide (TrA), directly into the affected areas.
Narges Ghandi, Atiyeh Rashidi, Fatemeh Saberi, Robabeh Abedini, Nasim Tootoonchi, Hanie Babaie   +5 more
wiley   +1 more source

Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark

Acta Dermato-Venereologica
The emergence of new systemic treatments for alopecia areata underscores the importance of estimating rates of potential treatment safety events among individuals with alopecia areata.
Sissel Brandt Toft Sørensen, Prethibha George, Oladayo Jagun, Robert Wolk, Lynne Napatalung, Samuel H. Zwillich, Lars Iversen, Vera Ehrenstein   +7 more
doaj   +1 more source

Oligosecretory Myeloma With Amyloidosis and Alopecia

Journal of Investigative Medicine High Impact Case Reports, 2018
Amyloidosis is a systemic illness characterized by the extracellular deposition of abnormal proteins in body tissues and organs. In addition to renal involvement, amyloidosis can also present with a variety of skin manifestations, though rarely with ...
Anum Bilal MD, Paul Der Mesropian DO, Franklin Lam MD, Gulvahid Shaikh MBBS   +3 more
doaj   +1 more source

Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata

Journal of Cosmetic Dermatology, Volume 24, Issue 7, July 2025.
ABSTRACT Background Alopecia areata (AA) is an autoimmune disorder mediated by T cells, resulting in hair loss on the scalp, eyebrows, and body. Conventional treatments for AA often exhibit high recurrence rates and various side effects. Recently, Janus kinase (JAK) inhibitors have emerged as promising therapeutic options for managing AA and several ...
Longyan Yao, Jiumei He, Na Lan, Yongmei Lv   +3 more
wiley   +1 more source

A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata

Pediatric Dermatology, Volume 42, Issue 4, Page 742-746, July/August 2025.
ABSTRACT Background Alopecia areata (AA) is an autoimmune disease characterized by hair loss that can negatively impact quality of life. AA has a significant pediatric prevalence; however, no systemic treatments are approved for AA in patients aged < 12 years. Ritlecitinib, a JAK3/TEC family kinase inhibitor, is approved to treat adults and adolescents
Mercedes E. Gonzalez, John Browning, Stacy Smith, Anna Plotka, Jing “Daisy” Zhu, Shyam Parvatini, Yeamin Huh, Robert Wolk   +7 more
wiley   +1 more source

Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 6, Page 1108-1118, June 2025.
ABSTRACT Ritlecitinib is a kinase inhibitor drug recently approved for the treatment of alopecia areata (AA) in both adults and adolescents based on a single, combined Phase 2b/3 study. Various QD doses with and without a loading dose have been evaluated in the pivotal Phase 2b/3 study.
Yeamin Huh, Ruolun Qiu, John Prybylski, Jessica Wojciechowski, Yuchen Wang, Vivek S. Purohit   +5 more
wiley   +1 more source

The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD—An Umbrella Review

Alimentary Pharmacology &Therapeutics, Volume 61, Issue 12, Page 1854-1871, June 2025.
Evidence for medical therapies targeting joint, skin and eye EIMs in IBD is heterogeneous and of low certainty. Multidisciplinary care and development of standardised, more appropriate outcome measures are essential to improve evaluation and guide future research. ABSTRACT Background Extraintestinal manifestations (EIMs) occur commonly in patients with
Olga M. Nardone, Nurulamin M. Noor, Aniruddh Prabhu, Alessandra Lim, Anirudh Krishnakumar, Abdulaziz Alajmi, Yuhong Yuan, Vipul Jairath, Maria Manuela Estevinho, Virginia Solitano   +9 more
wiley   +1 more source

Inflammatory Nail Disorders in Skin of Color: A Systematic Review of Clinical and Onychoscopic Manifestations

International Journal of Dermatology, Volume 64, Issue 6, Page 1013-1020, June 2025.
ABSTRACT Despite increasing attention regarding skin diseases in individuals with skin of color (SoC), there remains a significant gap in understanding and identifying inflammatory nail disorders in this population. This systematic review aims to synthesize the clinical and onychoscopic features of inflammatory nail disorders in patients with SoC ...
Lea Tordjman, Jason Thomas, Antonella Tosti, Brian W. Morrison   +3 more
wiley   +1 more source

Evidence Based Treatment of Alopecia Areata

Berkala Ilmu Kesehatan Kulit dan Kelamin (Periodical of Dermatology and Venerology), 2017
Background: Alopecia areata is a chronic autoimmune disease, involving non-scarring hair loss, which affects hair follicles and sometimes nails. Hair loss pattern presents as patchy alopecia, ophiasis, ophiasis inversa (sisapho), reticularis or diffuse ...
Eva Hariani, Nelva K. Jusuf
doaj   +1 more source

Alopecia Areata and Systemic Lupus Erythematosus: Insights From a Nationwide Case–Control Study

International Journal of Dermatology, EarlyView.
Yonit Wohl, Annabel Maruani, Amir Bentov, Yarden Drutin, Jacob Mashiah   +4 more
wiley   +1 more source